access pharma logo Access Pharmaceuticals

  • About Us
    • Board of Directors
    • Senior Management
  • Product Programs
    • MuGard
    • ProLindac
      • Chemistry
      • Preclinical data
      • Future Development
    • Cobalamin mediated oral drug delivery
    • Thiarabine
    • Cobalamin targeted delivery
    • Publications
  • Business Development
  • Investor Relations
  • Newsroom
    • 2010
    • 2009
  • Contact Us
Loading....
  • Stock Quote

    ACCP (OTCBB)
    Last Trade
    Change
    Open
    Bid
    Ask
    Volume
    2.00
    0.00 
    N/A
    1.90
    2.00
    0
    *quotes delayed at least 15 minutes
     


  • Contacts

    • 2600 Stemmons Freeway,
    • Suite 176
    • Dallas, TX 75207-2107
    • Tel: (214) 905-5100
    akc@accesspharma.com
  • Sign Up For News Alerts





  • Management Team


    Jeffrey B. Davis
    Chief Exec. Officer



    Stephen B. Thompson
    Vice President and CFO



    David P. Nowotnik, Ph.D. 
    Senior Vice President of Research and Development


    Esteban Cvitkovic, M.D. 
    Vice Chairman, Senior Director, Oncology Clinical R&D


    Phillip S. Wise, MBA 
    VP of Bus. Devel. & Strategy

  • On the Web



  • Latest Tweets


     Follow Us
  • Accesspharma: RT @Gastro_Digestiv: (OTCBB: ACCP) FDA Approved MuGard Targets $1 Billion Market: Access Pharma CEO Jeffrey Davi... http://bit.ly/94TNJ
    6:47 pm Aug 31st
  • Accesspharma: RT @ProActiveNR: Part II - Q&A with Jeff Davis of Access Pharma (OTCBB: ACCP) http://tinyurl.com/2duc8h4
    6:40 pm Aug 31st
  • Accesspharma: RT @wkpetersbiz: Why MuGard will be successful. http://www.themarketfinancial.com/why-mugard-will-be-successful#
    6:39 pm Aug 31st
  • Accesspharma: @wkpetersbiz Thanks wkpetersbiz for the Access Pharma mention ... Jeff
    6:39 pm Aug 31st
  • Accesspharma: @RitaBiotech Thanks RitaBiotech for the mention ... Jeff
    6:39 pm Aug 31st
  • News and Articles on Proactiveinvestors.com

    • Access Pharma and iMedicor start marketing program for MuGard
    • Access Pharma signs up BioScrip to distribute MuGard in US
    • Access Pharma lands pre-licensing deal to develop oral formulation of injectable drugs
    • Access Pharmaceuticals to Bring MuGard to Market in US in Q3
    • Access Pharma CEO Davis to meet investors in New York ahead of MuGard launch
  • Categories

    • Calendar and Coverage (36)
    • Clinical data (23)
    • Corporate (7)
    • Product programs (71)
      • Cobalamin (10)
      • MuGard (33)
      • ProLindac (11)
      • Thiarabine (4)
    • Strategic partnerships (36)
      • Asia (6)
      • Europe (7)
      • North America (8)
  • Archives

    • 2010
      • January (4)
      • February (2)
      • March (3)
      • April (4)
      • May (1)
      • June (5)
      • July (6)
      • August (4)
      • September (1)
    • 2009
      • January (2)
      • February (1)
      • March (1)
      • April (1)
      • May (2)
      • June (6)
      • July (6)
      • August (5)
      • September (4)
      • October (4)
      • November (2)
      • December (2)
    • 2008
      • January (2)
      • February (1)
      • March (1)
      • April (2)
      • May (3)
      • June (2)
      • July (1)
      • August (2)
      • September (1)
      • October (2)
      • November (1)
      • December (1)
  • Resources

    Corporate Presentation
    Corporate Fact Sheet
    Scientific Publications
    ProLindac™ Fact Sheet
    MuGard™ Fact Sheet
    Cobalamin™ Fact Sheet
    Thiarabine Fact Sheet
    Analyst Report - August 18, 2010
    Analyst Report - July 27, 2010
    Analyst Report - May 18, 2010
    Analyst Report - Dec. 16, 2009
    Analyst Report - Jul. 30, 2009
    Analyst Report - Jul. 6, 2009
    Analyst Report - Apr. 23, 2009

  • Tags

    ACCP Accupac acquisitions acute lymphocytic leukemia acute myeoid leukemia analyst report ASK B12 bioRASI BioScrip breast cancer Clinical data Cobalamin conferences DACH platinum drug diabetes drug delivery financing imedicor intellectual property interviews JCOM MacroChem MASCC media coverage MuGard news oral insulin oral mucositis outsidein research ovarian cancer Pexiganan pipeline product opportunities ProLindac rheumatoid arthritis RNAi Rodman & Renshaw LLC Somanta SpePharm Strategic partnerships targeted cancer therapy Thiarabine vmci zacks
  • Images


© Access Pharmaceuticals 2010 | Disclaimer